| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite Human Endogenous Metabolite
The primary target of N-Methylnicotinamide is the enzyme Nicotinamide N-methyltransferase (NNMT). NNMT is a metabolic enzyme involved in controlling methylation potential, impacting DNA and histone epigenetic modification. NMN itself acts as a metabolite with biological activities on endothelial cells. |
|---|---|
| ln Vitro |
N-Methylnicotinamide exhibits antithrombotic effects via production and release of prostacyclin, which inhibits arterial thrombosis development. It has multiple effects on endothelial cells: it inhibits thrombus formation, increases skin vascular permeability, and prevents atherosclerosis in rodent models. NMN has been shown to protect against endothelial dysfunction and attenuate atherogenesis in animal models.
|
| ln Vivo |
In vivo, N-Methylnicotinamide has been shown to prevent atherosclerosis in rodent models. It protects against endothelial dysfunction and attenuates atherogenesis. The compound's antithrombotic effect is mediated through prostacyclin production and release. NMN is an endogenous metabolite that is involved in nicotinate and nicotinamide metabolism pathway.
|
| Enzyme Assay |
In vitro enzyme assays for NNMT involve incubating the enzyme with N-methylnicotinamide and S-adenosylmethionine (SAM) as methyl donor in Tris-HCl buffer at pH 7.4. The reaction product, S-adenosylhomocysteine (SAH), is quantified by HPLC or LC-MS/MS. Enzyme activity is measured by monitoring the methylation of nicotinamide to N-methylnicotinamide. Kinetic parameters are determined by varying substrate concentrations.
|
| Cell Assay |
For in vitro cell assays, endothelial cells are cultured in medium supplemented with N-Methylnicotinamide at concentrations of 0.1-10 mM. Cell viability is assessed by MTT assay. Anti-thrombotic effects are evaluated by measuring prostacyclin production using ELISA. Endothelial function is assessed by measuring nitric oxide production and vasorelaxation responses. Anti-inflammatory effects are evaluated by measuring cytokine levels.
|
| Animal Protocol |
For in vivo animal studies, N-Methylnicotinamide is administered to rodents via oral gavage or intraperitoneal injection at doses of 10-100 mg/kg. Blood and tissue samples are collected for pharmacokinetic analysis. Anti-atherosclerotic effects are evaluated in atherosclerosis models by measuring plaque formation. Thrombus formation is assessed in arterial thrombosis models. Plasma NMN levels are quantified by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
N-methylnicotinamide is excreted in urine. N-Methylnicotinamide (MW 136.15) is soluble in DMF (15 mg/ml), DMSO (15 mg/ml), Ethanol (2.5 mg/ml), and PBS pH 7.2 (10 mg/ml). The compound is stable under standard storage conditions. As an endogenous metabolite, it is absorbed and metabolized through nicotinate and nicotinamide metabolism pathways. It is an investigational drug with no approved indications. |
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As an endogenous metabolite, it is expected to have low toxicity at physiological concentrations. The compound's effects on endothelial function and thrombosis suggest potential cardiovascular effects at higher doses. Standard safety precautions should be followed.
|
| Additional Infomation |
N-Methylnicotinamide is a pyridine carboxamide, a compound in which one amide hydrogen atom in the nicotinamide molecule is replaced by a methyl group. It is a metabolite functionally related to nicotinamide. N-Methylnicotinamide is an investigational drug with no approved indications or marketed formulations. It is a metabolite of nicotinamide/nicotinamide and nicotinic acid/nicotinic acid (vitamin B3), therefore, detecting N-methylnicotinamide levels in urine can be used to diagnose niacin deficiency.
Drug Indications N-Methylnicotinamide is an investigational drug with no approved indications. N-Methylnicotinamide (CAS# 114-33-0) is an endogenous metabolite and investigational compound used primarily in studies of cardiovascular disease, endothelial function, and methylation metabolism. It has not been approved for any therapeutic indication. The compound is of interest in the context of cardiovascular diseases, diabetes, and other metabolic disorders. It is used as a research tool to study NNMT function and nicotinamide metabolism. |
| Molecular Formula |
C7H8N2O
|
|---|---|
| Molecular Weight |
136.15
|
| Exact Mass |
136.064
|
| CAS # |
114-33-0
|
| Related CAS # |
N-Methylnicotinamide-d4;2708278-64-0
|
| PubChem CID |
64950
|
| Appearance |
White to off-white solid powder
|
| Density |
1.106 g/cm3
|
| Boiling Point |
347.7ºC at 760 mmHg
|
| Melting Point |
103.5 °C
|
| Flash Point |
164.1ºC
|
| Vapour Pressure |
5.3E-05mmHg at 25°C
|
| Index of Refraction |
1.529
|
| LogP |
0.832
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
125
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])N=C([H])C([H])=C1[H])N([H])C([H])([H])[H]
|
| InChi Key |
ZYVXHFWBYUDDBM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H8N2O/c1-8-7(10)6-3-2-4-9-5-6/h2-5H,1H3,(H,8,10)
|
| Chemical Name |
N-methylpyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (1836.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (15.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (15.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (15.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3448 mL | 36.7242 mL | 73.4484 mL | |
| 5 mM | 1.4690 mL | 7.3448 mL | 14.6897 mL | |
| 10 mM | 0.7345 mL | 3.6724 mL | 7.3448 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
